Which gene mutation does capmatinib mainly inhibit?

Capmatinib (Capmatinib), as an innovative targeted therapy drug, its core target is to target patients with non-small cell lung cancer (NSCLC) who have specific mutations in the MET gene. In this disease, the key mutation is the exon 14 skipping mutation of the MET gene, which is also referred to as the METex14 mutation by the medical community.

Under normal circumstances, the MET gene regulates various basic functions of cells, such as growth, proliferation and survival, by encoding receptor tyrosine kinases. But when there is a skip mutation in exon 14 of the MET gene, it will lead to abnormal activation of signaling pathways. This mutation makes the normal cell regulatory mechanism ineffective, thereby accelerating the proliferation and spread of tumor cells.

In order to deal with this problem,Capatinib blocks its abnormal signaling by precisely inhibiting the activity ofMET receptor tyrosine kinase. This approach can effectively curb the growth of tumors triggered by METex14 mutations.

It is worth mentioning that capatinib (capatinib) ’s high selectivity allows it to more accurately attack tumor cells carrying METex14 mutations while reducing the impact on healthy cells. This targeting not only enhances the therapeutic effect, but also reduces the side effects of the drug, thereby improving patient tolerance and quality of life.

In multiple clinical trials,capatinib has shown impressive results in the treatment of METex14 mutated advanced or metastatic non-small cell lung cancer. Among them, the GEOMETRY mono-1 study highlighted the outstanding performance of capatinib (capatinib) in prolonging the progression-free survival of patients and improving the objective response rate.

However, despiteCapatinib has remarkable efficacy, but patients still need to pay attention to possible side effects when using it, such as peripheral edema, gastrointestinal symptoms, etc. More serious side effects, such as interstitial lung disease and liver damage, also require great attention. Therefore, when patients receive capmatinib (capatinib) treatment, they should undergo regular physical examinations and make adjustments and monitoring under the guidance of a doctor.